| Management of sexuality, intimacy, and menopause symptoms in patients with ovarian cancer M Whicker, J Black, G Altwerger, G Menderes, J Feinberg, E Ratner American journal of obstetrics and gynecology 217 (4), 395-403, 2017 | 59 | 2017 |
| Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors ZP Lin, ES Ratner, ME Whicker, Y Lee, AC Sartorelli Molecular cancer research 12 (3), 381-393, 2014 | 50 | 2014 |
| Efficacy and safety of higher dose stereotactic radiosurgery for functional pituitary adenomas: a preliminary report RA Grant, M Whicker, R Lleva, JPS Knisely, SE Inzucchi, VL Chiang World neurosurgery 82 (1-2), 195-201, 2014 | 49 | 2014 |
| Ten-year comparison study of type 1 and 2 endometrial cancers: risk factors and outcomes J Feinberg, B Albright, J Black, L Lu, R Passarelli, S Gysler, M Whicker, ... Gynecologic and Obstetric Investigation 84 (3), 290-297, 2019 | 41 | 2019 |
| Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair ES Ratner, YL Zhu, PG Penketh, J Berenblum, ME Whicker, PH Huang, ... British Journal of Cancer 114 (7), 777-786, 2016 | 32 | 2016 |
| MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib ME Whicker, ZP Lin, R Hanna, AC Sartorelli, ES Ratner BMC cancer 16, 1-12, 2016 | 24 | 2016 |
| The management of sexuality, intimacy, and menopause symptoms (SIMS) after prophylactic bilateral salpingo-oophorectomy: How to maintain sexual health in “previvors” M Alexandre, J Black, M Whicker, MJ Minkin, E Ratner Maturitas 105, 46-51, 2017 | 20 | 2017 |
| Natural language processing approaches to understand HPV vaccination sentiment KA McGregor, ME Whicker Journal of Adolescent Health 62 (2), S27-S28, 2018 | 13 | 2018 |
| Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer AE Garcia‐Soto, ND McKenzie, ME Whicker, JM Pearson, EA Jimenez, ... Cancer 127 (13), 2279-2293, 2021 | 8 | 2021 |
| Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer BB Albright, JD Black, R Passarelli, S Gysler, M Whicker, G Altwerger, ... Gynecologic Oncology Reports 23, 28-33, 2018 | 5 | 2018 |
| A Social Media Exploration of Pro-Anorexia Groups: How to Reduce Risk, Increase Autonomy, and Create Healthy Online Communities KA McGregor, OM Clancy, ME Whicker Journal of Adolescent Health 66 (2), S58-S59, 2020 | 2 | 2020 |
| A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression SB Gitto, M Whicker, G Davies, S Kumar, K Kinneer, H Xu, A Lewis, ... Clinical Cancer Research 30 (8), 1567-1581, 2024 | 1 | 2024 |
| Abstract B060: Dual blockade of BRD4 and the ATR/WEE1 pathway exploits ARID1A loss in clear cell ovarian cancer Y Kinose, H Xu, S Kumar, H Kim, S Medvedev, X Wang, E George, ... Molecular Cancer Therapeutics 22 (12_Supplement), B060-B060, 2023 | | 2023 |
| Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer F Simpkins, Y Kinose, H Xu, H Kim, S Kumar, X Shan, E Geroge, X Wang, ... | | 2023 |
| Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer Y Kinose, H Xu, H Kim, S Kumar, X Shan, E George, X Wang, ... Research Square, 2023 | | 2023 |
| Abstract PR11: Dual blockade of BRD4 and the ATR/WEE1 pathway exploits ARID1A loss in clear-cell ovarian cancers Y Kinose, H Kim, H Xu, S Medvedev, E George, S Gitto, M Whicker, ... Clinical Cancer Research 26 (13_Supplement), PR11-PR11, 2020 | | 2020 |
| A comparison of tumor size at diagnosis and disease recurrence in type I and type II endometrial carcinoma ME Whicker, KA McGregor, JD Black, R Passarelli, B Albright, S Gysler, ... Gynecologic Oncology 145, 132, 2017 | | 2017 |
| The impact of tumor fragments in the lumen of fallopian tubes on recurrence and survival in type I and type II endometrial cancers JD Black, R Passarelli, L Lu, B Albright, S Gysler, ME Whicker, ... Gynecologic Oncology 145, 129, 2017 | | 2017 |
| A Ten-Year Single Institution Experience Comparing Type 1 and Type 2 Endometrial Cancers J Black, R Passarelli, M Whicker, S Gysler, B Albright, L Lu, G Menderes, ... REPRODUCTIVE SCIENCES 24, 203A-203A, 2017 | | 2017 |
| MK-2206 sensitizes BRCA2 mutant ovarian adenocarcinoma to cisplatin and poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitor therapy ME Whicker, ZP Lin, AC Sartorelli, ES Ratner Gynecologic Oncology 133, 86-87, 2014 | | 2014 |
